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ABSTRACT 
   Purpose: Brachytherapy is one of the most efficient methods of overcoming endobronchial obstruc-
tion in palliative treatment of lung cancer. In single cases, brachytherapy is performed as radical 
treatment, however in most of cases, due to advanced clinical stage it has a palliative aim. In the ab-
sence of clear consensus regarding the value of doses used in brachytherapy different fraction doses 
are used in clinical treatment. The aim of this work is to compare results of palliative high dose rate 
brachytherapy using various treatment protocols with the view to analysing differences in survival 
and diminishing breathing difficulties.  
   Material and methods: Between May 1999 and February 2000 at the Greatpoland Cancer Center, 
69 patients with advanced lung cancer were treated by high dose rate brachytherapy. They were 
disqualified from radical treatment due to advanced clinical stage. The age of the patients ranged from 
39 to 76 years (average 53,2 years). Fifty-one patients received a total dose of 22,5 Gy in 3 fractions 
once a week, 18 patients received one single fraction of 10 Gy. All the patients were divided into two 
groups according to their clinical stage and the Karnofsky score – those with the Karnofsky score 
lower than 50 were qualified for a single fraction treatment. They were under clinical and endobron-
chial observation as regards survival rates, local remission and subsiding dyspnoea, breathing, cough 
and haemoptysis in the first, third, sixth and twelveth month of observation. 
   Results: Four weeks after the end of treatment subjective improvement (subsidence of all symp-
toms) was ascertained in 61/69 (88,4%) patients. In 12 cases (17,4%) complete remission (CR), 
in 49 cases (71,0%) - partial remission (PR) of the tumor were found. During one year of observa- 
tion 45 (65,2%) patients died, in 10 cases (14,5%) improvement of in dyspnoea was observed 
and in 14 cases (20,3%) recurrence and progression of the disease were noted. There was no 
statistical difference in the survival rates between the two groups of patients treated with different 
fractions protocols. 
   Conclusions:
1. Brachytherapy in advanced lung cancer is an efficient method that led in most of patients 
to subcidence of symptoms and to improvement of the quality their lives.  
2. The two treatment protocols showed similar efficiency in overcoming difficulties in breathing. 
3. Survival rates were similar in both group of patients treated with different treatment protocols. 
   Key words: lung cancer, HDR brachytherapy.
INTRODUCTION 
   Brachytherapy is one of the most effi-
cient methods in the overcoming diffi-
culties in breathing caused by endobron-
chial obstruction in palliative treatment 
of lung cancer [1-5]. Depending on the lo-
cation of the lesion in some cases bra-
chytherapy is a treatment of choice. 
Because of the uncontrolled local or re-
current disease, patients may have 
significant  symptoms:  cough,  dyspnoea,  
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haemoptysis, obstructive pneumonia 
or atelectasis. In many patients, these 
symptoms are primarily attributable to en-
dobronchial obstruction. Efforts to relieve 
this obstructive process are worthwhile 
because patients may experience a signi-
ficantly improved quality of life. However, 
many of these patients have a poor per-
formance status and have received multi-
ple other therapies. As a result, treatment 
options are often limited. 
   In most cases brachytherapy has a pa-
lliative aim due to the advanced clinical 
stage [6-9]. Lack of clear consensus regar-
ding the value of doses used in brachy-
therapy is the reason why different frac- 
tion doses are used in clinical treatment 
[3,10-12].   
   Due to bad performance status (Karnof-
sky score < 50) single high doses ranging 
from 10 Gy to 15 Gy are used [3,11,13]. 
It seems that the results achieved are 
similar to those when doses are given 
weekly in two or three fractions. A single 
dose protocol is cost - sparing and com-
fortable for patients. On another hand, 
weekly repeated treatment makes it possi-
ble to have an better local control 
visualized on bronchoscopy. 
   The aim of this work was to compare 
results of palliative high dose rate brachy-
therapy using various treatment protocols, 
especially with a view to analysing diffe-
rences in survival rates and the dimini-
shing breathing difficulties. 
MATERIAL AND METHODS 
   Between May 1999 and February 2000, 
69 patients with advanced lung cancer 
were treated palliatively using High Dose 
Rate brachytherapy at the Great Poland 
Cancer Centre. They were disqualified 
from radical treatment (eg. surgery, exter-
nal beam therapy) due to advanced cli-
nical stage. Brachytherapy was chosen as 
the only method of treatment due to endo-
bronchial obstruction caused by a visuable 
tumour and because of intensive dys-
pnoea was selected instead of external 
beam therapy.  
   The age of the patients (54 males and 
15 females) ranged from 39 to 76 years 
(average 53,2 years). Fifty-six patients had 
T3N1-2 and 13 – T4Nx clinical stage, 
respectively. In most cases (n=56) more 
than 50% of the bronchus were obturated 
by the tumour.  
   In all the cases tumour was localized 
in one of the main bronchus. The intra-
bronchial tumour occlusion in this group 
was single cause for dyspnoea. 
   The most frequent histopatological type 
was squamous cell carcinoma (n=61), 
adenocarcinoma being diagnosed in 8 pa-
tients (Table 1).
Tab. 1. Clinical characteristic of patients 
                     Clinical data Number of patients 
(1) Age: 
<53,2 30 (43,5%) 
>53,2 39 (56,5%) 
Average: 53,2 
(2) Sex: 
Male: 54 (78,3%) 
Female: 15 (21,7%) 
(3) Symptoms: 
Dyspnoea: 69 (100,0%) 
Caugh: 60   (87,0%) 
Hemoptysis: 37   (53,6%) 
Pain: 13   (18,9%) 
Atelectasis: 11   (15,9%) 
(4) Histopathological type:
squamous cell carcinoma 61 (88,4%) 
adenocarcinoma   8 (11,6%) 
(5) Clinical stage: 
T3 N1 33 (47,7%) 
T3 N2 23 (33,3%) 
T4 N0-X 13 (18,9%) 
(6) Methods of treatment: 
3 x 7,5 Gy 51 (73,9%) 
1 x 10 Gy 18 (26,1%) 
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   Patients were divided into two groups 
according to their clinical stage and the 
Karnofsky score; patients were qualified 
for single fraction treatment (10 Gy) when 
the Karnofsky score was lower than 50.  
   A single bronchial catheter (diameter 
of 1,8 mm) was fixed in the bronchus 
during bronchoscopy. The target volume 
included the tumor with a 2 cm margin 
proximally and distally. The dose was 
measured 1 cm from the catheter axis. 
An iridium 192 source with 10 Ci nominal 
activity and GAMMAMED 12i and an ABA-
CUS planning system were used. 
   Fifty-one patients received a total dose 
of 22,5 Gy in three fractions given once 
a week, whereas 18 patients received one 
single fraction dose of 10 Gy. 
   Clinical and endobronchial observations 
included rating of local remission and sub-
ciding difficulties with breathing, cough, 
pain and haemoptysis in the first, third, 
sixth and twelveth month of observation. 
The results achieved were assessed using 
bronchoscopy and clinical examination af-
ter the end of brachytherapy. The results 
were divided into four categories: (1) com-
plete remission (CR) – subciding symp-
toms and total regression observed during 
bronchoscopy, (2) partial remission (PR), 
(3) no remission (NR), or (4) progression. 
Local (assessed during bronchoscopy) 
and clinical (subjective) remission and sur-
vival rates were compared with two diff-
erent fractionation protocols. The material 
was analyzed on the basis of retrospective 
observation of the course of the disease. 
Statistical analysis was performed using 
the F. Cox test. Survival rates were 
analyzed using the Kaplan-Meier method. 
RESULTS 
   After four weeks from the end of the tre-
atment subjective improvement (subciden-
ce of all symptoms) was ascertained 
in 61/69 (88,4%) patients (Table 2).
In 12 cases (17,4%), complete remission 
(CR), in 49 (71,0%) partial remission (PR) 
of the tumour and in 8 (11,6%) no remi-
ssion (NR) or progression were found on 
bronchoscopy and X-ray examination.  
Tab. 2. Improvement in symptoms in comparison with clinical data (CR + PR). 
Clinical data N = 1 month 3 month 6 month 12 month 
(1) Age: 
< 53,2 years 
> 53,2 years 
(2) Sex: 
Male:
Female: 
(3) Histopathology: 
squamous cell carcinoma 
adenocarcinoma 
(4) Clinical stage: 
T3 N1 
T3 N2 
T4 N0-X 
30
39
54
15
61
8
33
23
13
86,7% 
89,7% 
90,7% 
80,0% 
88,5% 
87,5% 
90,1% 
86,6% 
84,6% 
80,0% 
84,6% 
88,9% 
60,0% 
83,6% 
75,0% 
87,9% 
82,6% 
53,9% 
46,7% 
61,5% 
57,4% 
46,7% 
57,4% 
37,5% 
57,4% 
55,1% 
38,5% 
6,7% 
20,5% 
14,8% 
13,3% 
14,8% 
12,5% 
33,3% 
8,3% 
0,0% 
CR – complete remission 
PR – partial remission 
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   After three months, CR was noted 
in 10/69 (14,5%) cases, PR in 47/69 
(68,1%) cases, NR in 9/69 (13,0%) cases 
and three cases (4,3%) showed progre-
ssion. After 6 months, CR was observed 
in 8/69 (11,6%) cases, PR in 30/69 
(43,5%) cases and progression/recurren-
ce in 19/69 (27,5%) cases. Twelve (17,4%) 
patients died in the first 6 months of obser-
vation. After 12 months of observation, 
in 10 (14,5%) cases improvement in dys-
pnoea (CR + PR) was seen and in 14 
(20,3%) cases recurrence and progre-
ssion of the disease (Table 3) was noted. 
During one year of observation 45 (65,2%) 
patients died. 
   Four weeks after the end of treatment 
the results in both groups of patients were 
compared. In a group of 51 patients trea-
ted with three fractions of 7,5 Gy CR was 
observed in 9 (17,7%) cases, PR in 37 
(72,6%) cases and NR/progression 
in 5 (9,8%) cases. In a group of 18 pa-
tients treated with a single 10 Gy fraction 
the following results were obtained: CR 
in 3 (16,7%) cases, PR in 12 (66,7%) 
cases and NR/progression in 3 (16,7%) 
cases. The median survival time for both 
groups was 26 weeks. The greatest risk 
of death was observed in the 24th week 
in both groups. There was no statistically 
important difference in the results 
(the length of survival time) between 
the two groups of patients treated with 
different doses (p = 0,26) (Figure 1).
Also failed to observe any differences after 
3,6 and 12 months (Table 4).
   In fifteen cases, superficial necrosis was 
observed in the third and sixth month 
of observation. Another frequent early 
complications were: cough, high tempe-
rature and weakness. In four cases 
(5,8%), during 12 months of observation, 
we found a broncho - esophageal fistula – 
two in both groups of patients. Compli-
cations occurred also in both groups 
of patients.  
Tab. 3. Improvement in symptoms in patients examined (CR + PR). 
Symptoms N = 1st month 3rd month 6th month 12th month 
Dyspnoea 
Caugh 
Hemoptysis 
Pain 
Atelectasis 
69
60
37
13
11
88,4% 
91,7% 
91,9% 
76,9% 
90,1% 
83,2% 
88,7% 
79,3% 
76,9% 
90,1% 
55,1% 
65,7% 
65,7% 
70,1% 
82,2% 
41,7%* 
41,7%* 
37,5%* 
37,5%* 
37,5%* 
* relating to living patients 
CR – complete remission 
PR – partial remission 
Tab. 4. Comparison of the effectiveness of both methods of treatment (CR = PR). 
Methods 
of treatment 
N = 
1st month 
n =      % 
3rd month 
n =      % 
6th month 
n =      % 
12th month 
n =      % 
1/ 3 x 7,5 Gy 
2/ 1 x 10 Gy 
51
18
46 (90,2%) 
15 (83,2%) 
44 (86,3%) 
13 (72,3%) 
27 (52,9%) 
11 (61,1%) 
7 (13,7%) 
3 (16,7%) 
Total 69 88,4% 82,6% 55,1% 14,5% 
CR – complete remission 
PR – partial remission 
Skowronek et al.: High dose rate endobronchial … 
Rep. Pract. Oncol. Radiother. 7 (3) 2002 
Fig. 1. Cumulative proportion (surviving Kaplan-Meier) for groups 1 (3 x 7,5 Gy) and 2 (1 x 10 Gy). F Cox test (p = 0.26). 
DISCUSSION 
   An airway obstruction secondary to ex-
tensive primary or recurrent intrathoracic 
cancer, occurs frequently and creates 
devastating effects for many patients. 
There are many therapeutic modalities 
available that can be used to relieve this 
obstruction, including laser therapy, exter-
nal beam irradiation, chemotherapy, and 
endobronchial brachytherapy [1,4,14,15].  
   External beam irradiation, although 
effecttive, may not be possible in many 
patients (primarily those received prior 
treatment) because of the proximity of do-
se limiting structures adjacent to the tra-
cheobronchial tree (i.e. esophagus, spinal 
cord). In addition, external beam irra-
diation can have significant side effects 
(i.e. dysphagia) and result in unnecessary 
normal tissue damage. 
   Endobronchial brachytherapy provides 
prompt relief of symptoms in patients with 
intraluminal airway tumours. Although ex-
ternal-beam radiation therapy could also 
be used for this purpose, it cannot be often 
used because patients have already re-
ceived irradiation.  
   A lot of investigators have used a range 
of prescription points and fractional doses 
which may make direct comparisons be-
tween series difficult.  
   Kelly et al. [16] reported significant cli-
nical improvement in 32% of 175 sym-
ptomatic patients, slight improvement 
in 34% of patients, no relief in 17% of pa-
tients and worsening of symptoms in 10% 
of patients. For most of the applications, 
a dose of 15 Gy was given at a distance 
of 6mm; therefore, the most common total 
doses were multiples of this single dose, 
or 15 Gy (23%), 30 Gy (58%) and 45 Gy 
(7%). 
   Speiser and Spratling [17] observed 
symptomatic response rates of 85-99% 
in 342 patients receiving a range of HDR 
protocols divided into two groups – one 
treated with fraction of 10 Gy and the 
second treated with 7 Gy. Response rates 
were similar in both groups. Similarly, 
Gustafson et al [18] noted significant
clinical improvement in 74% of 38 sym-
ptomatic patients treated to 21 Gy at 1 cm 
given in 3 HDR applications over 3 weeks. 
Nori et al. [19] reported palliation rates 
ranging from 84% to 100% in 15 patients 
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receiving 12-16 Gy at 1 cm delivered 
in 3-4 HDR treatments given over one 
month. In the Bedwinek et al. [20] series, 
76% of the patients had symptomatic 
improvement in response to a dose of 18 
Gy, given at a distance of 1 cm in 3 HDR 
sessions weekly. 
   In our study, we examined the results 
of treatment of 69 patients with endo-
bronchial tumour treated with different 
doses of HDR brachytherapy. We found 
that significant and durable clinical and 
radiographic responses can be obtained 
in patients with symptoms despite prior 
radiation therapy or the presence 
of the metastatic, nonbronchogenic pri-
mary disease. There was no statistically 
important difference in the results between 
the two groups of patients treated with 
different doses. In addition, the morbidity 
associated with HDR endobronchial bra-
chytherapy appears acceptable despite 
late complications directly related to the 
procedure. The complication rate in our 
series compares favorably with those 
reported from other institutions [5,6,21]. 
Given these findings, we believe that HDR 
endobronchial brachytherapy can provide 
a safe, quick, and effective palliation 
method and should be recommended 
in patients with a symptomatic endobron-
chial disease. 
CONCLUSIONS 
1. Brachytherapy in advanced lung can-
cer is an efficient method that lead 
to subsidence in most of patients sym-
ptoms and to improvement in life qua-
lity.  
2. Both treatment protocols were charac-
terized by similar efficiency in overco-
ming dyspnoea, cough, pain and hae-
moptysis. 
3. Survival rates were similar in both 
group of patients treated with different 
protocols. 
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